Deadline for Abstract Submission: February 15, 2018
All abstracts will be evaluated by a jury comprised of members of the SPARTAN Research and Education committees. Scientifically sound abstracts with relevance to spondyloarthritis (basic, clinical or translational research) will be accepted for poster presentation. The highest ranked abstracts will in addition be invited for oral presentation.
Trainees include students, residents, fellows and postdocs. Results should not already have been published in a peer-reviewed journal. Abstracts presented at other meetings within one year are eligible for submission. Abstracts submitted to the 2018 SPARTAN meeting may also be submitted to the ACR 2018 Annual Scientific meeting.
Jury decisions will be announced by mid-March, 2018. We encourage trainees to register for the 2018 SPARTAN Annual Meeting at the time of abstract submission. Acceptance of an abstract for presentation is not a requirement for meeting attendance.
Posters will be displayed at the conference venue on May 3 and 4. We will have a poster viewing session in the evening of May 3. The highest ranked abstracts will be presented in an oral abstract session on May 4. Please note that we expect trainees with accepted abstracts to attend all sessions of the 2018 SPARTAN Annual Meeting from May 3 to May 5.
Abstract Submission Fee:
The abstract limit is 2,750 characters, which excludes the title, names of authors or co-authors, affiliations, spacing and disclosures. A maximum of 3 figures or tables is allowed. Each table or graphic will decrease the character count by 250 characters from the total limit allowed. Additional instructions:
- Titles: Titles should be brief, representing the nature of the research. Use mixed case (do not use all caps) and do not put a period at the end of the title.
Example: This is a Properly Formatted Abstract Title
Please refrain from using acronyms in your abstract title. Acronyms may remain in the body of the abstract and in the author list.
- Authors: Please consult with your co-authors on how they would like their names to appear. There is no limit on the number of authors for each abstract. All authors must disclose any relevant financial relationship(s) at the time of abstract submission.
- Content: Organize content as follows:
- Background: Background or Statement of Purpose
- Methods: Methods, materials and analytical procedure used
- Results: Summary of the results in sufficient detail to support conclusion
- Conclusion: Conclusions reached (do not state “results will be discussed”).
- Use of Product Names: The generic name should be used in your abstract. The proprietary drug name may appear once in parentheses in the title only. However, if a drug has not received FDA approval, only the non-proprietary name may be used in the title and abstract content.
- Abbreviations: Place abbreviations in parentheses after the first time the full word appears. Do not abbreviate compounds in the title of the abstract. Use numerals to indicate numbers, except when beginning sentences.
Any work with human or animal subjects reported in submitted abstracts must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
Questions? Please contact Lisa Spiegel